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Introduction
PVL is usually associated with non multiresistant com-
munity-acquired MRSA. However, the epidemiology of
PVL+-MRSA is changing.
Objectives
We describe the resistance patterns and molecular epi-
demiology of PVL+-MRSA isolates from 17 countries
around the world.
Methods
Retrospective laboratory-based survey from 2008 to
2010. Participating countries (Australia, Brazil, Canada,
China, Denmark, France, Germany, Greece, Hong Kong,
India, Italy, Japan, Korea, Malaysia, Netherland, Poland,
Switzerland) reported on susceptibility to 10 non-beta-
lactam antibiotics and MLST and/or spa typing of PVL+
MRSA isolates. A selection of 49 isolates were analysed
by MLVA.
Results
Overall, susceptibility data of 3236 was reported. The
lowest susceptibility was observed for erythromycin in all
regions (17.3% in the Americas and 60% both in Europe
and Asia&Oceania). Vancomycin-intermediate isolates
were reported from Hong Kong and The Netherlands.
Multiresistance (3 or more non-beta-lactams) was
reported from all regions. Isolates belonged to 8 clonal
complexes. ST30 was reported worldwide, being the
most frequent type in Brazil and Asia. ST8 was the most
frequent in Canada. In Europe, ST80 and ST8 were both
reported in the first place. Six major clusters were discri-
minated by this method, showing a certain geographic
specificity and agreement with MLST.
Conclusion
PVL+-MRSA remains frequently susceptible to non-
beta-lactam agents, with in vitro activity of vancomycin,
rifampicin, cotrimoxazole and linezolid. However, multi-
resistant isolates were reported from all regions. Our
results are in agreement with recent observations that
suggest that USA300 and related clones are gradually
replacing the European ST80 clone. It is imperative to
continue monitoring susceptibility patterns and molecu-
lar epidemiology of MRSA to provide clinicians with the
most up-to-date information.
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